Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC

Clinical trial NCT04399785 · UNKNOWN

Trial details

NCT number: NCT04399785
Sponsor: Xingchen Peng
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma

Start date: 2020-06-01
Primary completion: 2021-12-01
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.